By Diagnostics World Staff
September 17, 2024 | Daye, a women's health startup, is addressing the gender diagnostic gap with a novel self-sampling tampon that collects vaginal and cervical fluids for STI and HPV testing. Lindus Health collaborated with Daye to enroll 250 diverse participants and run the STAMP trial evaluating the efficacy of the diagnostic tampon for STIs and bacterial vaginosis (BV).
During the Next Generation Dx Summit, CEO Valentina Milanova and Lindus Health co-founder Meri Beckwith presented findings from the STAMP trial. This study, involving women aged 25 to 65, demonstrated that the diagnostic tampon was preferred by patients over swabs, showing higher diagnostic accuracy for conditions like bacterial vaginosis, chlamydia, and HPV. The tampon performed better than other self-sampling methods and clinician-administered tests.
Daye’s tampon kit, sent directly to patients' homes, is designed for easy use and can be returned to Daye’s labs for analysis. The trial results, set to be published soon, indicate that the tampon’s design allows for more comprehensive sample collection, reducing false positives and negatives.
This innovation is expected to increase participation in STI and HPV screening programs, offering women a more comfortable, accurate, and accessible option. For more details on the trial and Daye’s journey, read the full article at Clinical Research News.